These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9149065)

  • 21. Pharmacologic therapy for inflammatory bowel disease.
    Hirschfeld S; Clearfield HR
    Am Fam Physician; 1995 Jun; 51(8):1971-5. PubMed ID: 7762487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ulcerative colitis. Maintenance therapy].
    Kruis W; Schreiber S
    Z Gastroenterol; 2004 Sep; 42(9):1011-4. PubMed ID: 15455275
    [No Abstract]   [Full Text] [Related]  

  • 23. Role of rectal formulations: suppositories.
    Williams CN
    Scand J Gastroenterol Suppl; 1990; 172():60-2. PubMed ID: 2191425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypersensitivity to 5-aminosalicylic acid in patients with ulcerative colitis.
    Niv Y
    Isr J Med Sci; 1987 Nov; 23(11):1161-3. PubMed ID: 3436802
    [No Abstract]   [Full Text] [Related]  

  • 25. [A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis].
    Kim KH; Kim TN; Jang BI
    Korean J Gastroenterol; 2007 Dec; 50(6):379-83. PubMed ID: 18159175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypersensitivity to 5-aminosalicylic acid. Value of desensitization by oral route].
    Lachaux A; Le Gall C; Loras-Duclaux I; Aboufadel A; Hermier M
    Arch Pediatr; 1997 Feb; 4(2):144-6. PubMed ID: 9097825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.
    Campieri M; De Franchis R; Bianchi Porro G; Ranzi T; Brunetti G; Barbara L
    Scand J Gastroenterol; 1990 Jul; 25(7):663-8. PubMed ID: 2204103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Salazosulfapyridine or 5-aminosalicylic acid].
    van Hees PA
    Ned Tijdschr Geneeskd; 1987 May; 131(22):931-4. PubMed ID: 2885762
    [No Abstract]   [Full Text] [Related]  

  • 29. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proctocolitis unresponsive to conventional therapy. Response to 5-aminosalicylic acid enemas.
    McPhee MS; Swan JT; Biddle WL; Greenberger NJ
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):76S-81S. PubMed ID: 3319462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.
    Williams CN; Haber G; Aquino JA
    Dig Dis Sci; 1987 Dec; 32(12 Suppl):71S-75S. PubMed ID: 3319461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of mesalamine in rectal suspension diluted with distilled water.
    Henderson LM; Johnson CE; Berardi RR
    Am J Hosp Pharm; 1994 Dec; 51(23):2955-7. PubMed ID: 7879807
    [No Abstract]   [Full Text] [Related]  

  • 34. [Management of ulcerative colitis].
    Rammert Ch; Kullak-Ublick GA
    Ther Umsch; 2003 Mar; 60(3):145-50. PubMed ID: 12693317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 36. [5-Aminosalicylic acid in treatment of non-specific enteritis].
    Adrych K; Zaucha JM; Kryszewski A
    Wiad Lek; 1993 Nov; 46(21-22):833-6. PubMed ID: 7817574
    [No Abstract]   [Full Text] [Related]  

  • 37. [Changing treatment of inflammatory bowel diseases].
    Karvonen AL; Matikainen M; Turunen U
    Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809
    [No Abstract]   [Full Text] [Related]  

  • 38. Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?
    Yönal O; Hatemi G; Kaymakoğlu S
    Turk J Gastroenterol; 2012; 23 Suppl 2():21-4. PubMed ID: 23576086
    [No Abstract]   [Full Text] [Related]  

  • 39. [Recent therapeutic modalities in chronic inflammatory bowel diseases: 4- or 5-aminosalicylic acid?].
    Allgayer H; Klotz U; Böhne P; Schmidt M; Kruis W
    Z Gastroenterol; 1994 Nov; 32(11):647-50. PubMed ID: 7886975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Mesalazine].
    Engelhardt K; Mohr K
    Dtsch Med Wochenschr; 1995 May; 120(21):769-70. PubMed ID: 7781502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.